InvestorsHub Logo
Followers 31
Posts 1358
Boards Moderated 0
Alias Born 10/22/2013

Re: rteest post# 132

Thursday, 08/18/2016 10:54:53 AM

Thursday, August 18, 2016 10:54:53 AM

Post# of 1728
"We will continue to focus on the potent topoisomerase 1 inhibition of CRLX101’s payload, camptothecin, in topoisomerase 1-sensitive tumors. Our combinations with weekly paclitaxel and LYNPARZA™ (olaparib) are examples of ongoing trials that leverage CRLX101’s topoisomerase 1 inhibition in combination with chemotherapies and DNA damage repair agents.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DARE News